TG Therapeutics (TGTX) Earnings Date, Estimates & Call Transcripts $22.19 -0.19 (-0.85%) (As of 10/3/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 6EstimatedActual EPS (Aug. 6) $0.04 Beat By $0.08 Consensus EPS (Aug. 6) -$0.04 Conference Call TranscriptConference Call AudioEarnings Press Release Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueTGTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TGTX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Trade StocksInvest in the AI Boom: Top 5 Stocks to WatchHow do you spot the next big winner before everyone else? Trade Stocks has the answer, and it comes in the form of our exciting new sponsor: InsiderOwl. Click here to join Trade Stocks and receive your first Insider Owl report TG Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.02)($0.02)($0.02)Q2 20242($0.08)($0.04)($0.06)Q3 20242$0.03$0.04$0.04Q4 20242$0.10$0.11$0.11FY 20248$0.03$0.09$0.06TGTX Earnings Date and InformationTG Therapeutics last announced its quarterly earnings data on August 6th, 2024. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.08. The company had revenue of $73.47 million for the quarter, compared to analysts' expectations of $65.92 million. Its quarterly revenue was up 357.0% on a year-over-year basis. TG Therapeutics has generated $0.23 earnings per share over the last year ($0.23 diluted earnings per share) and currently has a price-to-earnings ratio of 96.5. Earnings for TG Therapeutics are expected to grow by 538.46% in the coming year, from $0.13 to $0.83 per share. TG Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off prior year's report dates.Read More TG Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/6/2024(Estimated)------- 8/6/2024Q2 2024($0.04)$0.04+$0.08$0.04$65.92 million$73.47 million 5/1/2024Q1 2024($0.05)($0.07)($0.02)($0.07)$54.60 million$63.47 million 2/28/2024Q4 2023($0.12)($0.09)+$0.03($0.09)$40.06 million$43.97 million 11/1/2023Q3 2023$0.29$0.73+$0.44$0.73$23.91 million$165.80 million 8/1/2023Q2 2023($0.26)($0.34)($0.08)($0.34)$17.39 million$16.07 million 5/1/2023Q1 2023($0.36)($0.28)+$0.08($0.28)$3.38 million$7.80 million Seven “Forever Stocks” could enrich shareholders for decades (Ad)A few weeks ago, I asked my research team to investigate the top 10 best-performing stocks of the last 30 years. And the results will shock you!Seven Stocks to buy and Hold Forever2/28/2023Q4 2022($0.26)($0.39)($0.13)($0.39)$0.04 million$0.08 million 11/10/2022Q3 2022($0.33)($0.26)+$0.07($0.26)$3.37 million$0.09 million 8/8/2022Q2 2022($0.49)($0.30)+$0.19($0.30)$0.09 million$0.59 million5/10/2022Q1 2022($0.55)($0.51)+$0.04($0.51)$1.54 million$2.02 million3/1/2022Q4 2021($0.62)($0.70)($0.08)($0.70)$9.90 million$2.32 million 11/4/2021Q3 2021($0.56)($0.65)($0.09)($0.65)$3.23 million$2.03 million 8/1/2021Q2 2021($0.48)($0.59)($0.11)($0.59)$3.69 million$1.55 million 5/10/2021Q1 2021($0.52)($0.69)($0.17)($0.69)$0.99 million$0.79 million 3/2/2021Q4 2020($0.57)($0.71)($0.14)($0.71)$0.04 million$0.04 million 11/9/2020Q3 2020($0.41)($0.73)($0.32)($0.73)$0.04 million$0.04 million8/10/2020Q2 2020($0.32)($0.47)($0.15)($0.47)$0.04 million$0.04 million 5/11/2020Q1 2020($0.36)($0.48)($0.12)($0.48)$0.04 million$0.04 million3/3/2020Q4 2019($0.45)($0.44)+$0.01($0.32)$0.04 million$0.04 million 11/12/2019Q4($0.36)($0.69)($0.33)($0.65)$0.04 million$0.04 million TG Therapeutics Earnings - Frequently Asked Questions When is TG Therapeutics's earnings date? TG Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates. Learn more on TGTX's earnings history. Did TG Therapeutics beat their earnings estimates last quarter? In the previous quarter, TG Therapeutics (NASDAQ:TGTX) reported $0.04 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.04) by $0.08. Learn more on analysts' earnings estimate vs. TGTX's actual earnings. How can I listen to TG Therapeutics's earnings conference call? The conference call for TG Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read TG Therapeutics's conference call transcript? The conference call transcript for TG Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does TG Therapeutics generate each year? TG Therapeutics (NASDAQ:TGTX) has a recorded annual revenue of $346.72 million. How much profit does TG Therapeutics generate each year? TG Therapeutics (NASDAQ:TGTX) has a recorded net income of $12.67 million. TGTX has generated $0.23 earnings per share over the last four quarters. What is TG Therapeutics's price-to-earnings ratio? TG Therapeutics (NASDAQ:TGTX) has a trailing price-to-earnings ratio of 96.48 and a forward price-to-earnings ratio of 170.69. What is TG Therapeutics's EPS forecast for next year? TG Therapeutics's earnings are expected to grow from $0.13 per share to $0.83 per share in the next year, which is a 538.46% increase. More Earnings Resources from MarketBeat Related Companies: Deciphera Pharmaceuticals Earnings Date Sage Therapeutics Earnings Date FibroGen Earnings Date Insmed Earnings Date Viatris Earnings Date Dr. Reddy's Laboratories Earnings Date Vaxcyte Earnings Date Sarepta Therapeutics Earnings Date Catalent Earnings Date Qiagen Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Nike’s Post-Earnings Drop Presents a Buying OpportunityMicron Stock Soars as AI Demand Fuels Big Q4 Earnings BeatGameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season? This page (NASDAQ:TGTX) was last updated on 10/3/2024 by MarketBeat.com Staff From Our PartnersThe world’s smartest man is in their crosshairsElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredMassive NVIDIA Sell-Off: Are We Headed for a Market Collapse?You may have heard about NVIDIA's CEO dumping shares of his own company. He sold 4.4 million shares this ye...Behind the Markets | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding TG Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.